Important safety information about ZOLADEX® (goserelin acetate implant).
ZOLADEX is a prescription medication approved for use in combination with flutamide (an antiandrogen) plus radiotherapy for locally advanced prostate cancer. Treatment with the combination should start 8 weeks prior to starting and continue during radiation therapy.
ZOLADEX is also approved to use alone for patients with advanced prostate cancer. ZOLADEX may help reduce the size of your cancer and reduce your symptoms (palliative treatment).
ZOLADEX, like other LHRH-As, may cause an initial rise in testosterone. When used alone, there may be a temporary worsening of prostate cancer symptoms at the start of therapy.
Common side effects that occurred during treatment with ZOLADEX plus flutamide and radiation therapy or ZOLADEX alone included hot flashes, decrease in sexual desire and/or ability to have erections, diarrhea, pain (general, pelvic, and bone), lower urinary tract symptoms, fatigue, nausea, breast growth, swelling, rash, upper respiratory infection, and sweating.
Please see full Prescribing Information for ZOLADEX.
|
CASODEX®
(bicalutamide) 50-mg Tablets Full Prescribing Information ZOLADEX® (goserelin acetate implant) 3.6 mg Depot Full Prescribing Information ZOLADEX® (goserelin acetate implant) 10.8 mg Depot Full Prescribing Information Site Map | Contact Us |
||
| Privacy Statement | Legal Information | |
|
CASODEX and ZOLADEX are registered trademarks of the AstraZeneca group of companies. This product information is intended for US audiences only. 239941 4/06 ©2008 AstraZeneca Pharmaceuticals LP. All rights reserved. |
||
| US Corporate Site | ||